Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 61-70

  Lambert, Olivier ^a   Bandilla, Dirk ^a   Iyer, Rupa ^b   Lakshmanan, Leonore Witchey ^c   Palepu, Nagesh ^d  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b TPM Laboratories Inc   (United States)

^c Pharma CMC/IP   (United States)

^d SciDose LLC   (United States)

Author keywords

Diluents; Epoprostenol; Formulation; Microbial activity; Pulmonary arterial hypertension; Stability

Indexed keywords

ARGININE; MANNITOL; PROSTACYCLIN; SODIUM CHLORIDE; TEZOSENTAN;

ARTICLE; ASPERGILLUS NIGER; BACTERIAL GROWTH; CANDIDA ALBICANS; CLOSTRIDIUM SPOROGENES; CONTROLLED STUDY; DRUG DETERMINATION; DRUG FORMULATION; DRUG POTENCY; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STABILITY; ESCHERICHIA COLI; FUNGUS GROWTH; HEMOLYSIS; INOCULATION; MICROORGANISM DETECTION; MOULD; NONHUMAN; PSEUDOMONAS AERUGINOSA; SHELF LIFE; STAPHYLOCOCCUS AUREUS; STORAGE TEMPERATURE; TEMPERATURE MEASUREMENT; THERMOSTABILITY;

EID: 84863751438     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/dddt.s29916     Document Type: Article

References (20)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425-1436.
2. Badesch DB, Abman SH, Ahearn GS, et al; American College of Chest Physicians. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(Suppl 1): 35S-62S.
3. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet. 1984;1(8385):1046-1047.
4. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990(7);112:485-491.
5. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996(5);334:296-302.
6. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425-434.
7. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-788.
8. Badesch DB, McGoon MD, Barst RJ, et al. Long-term survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009;36(10):2244-2249.
9. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S78-S84.
10. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34(6): 1219-1263.
11. Flolan® SPC. Available from: http://www.medicines.org.uk/emc/ medicine/7173/SPC/FlolanlInjectionI1.5mg/#PHARMACOLOGICAL_PROPS. Accessed March 3, 2011.
12. Veletri Prescribing Information. Available from: http://www.veletri. com/patient-prescribing-information.asp. Accessed March 3, 2011.
13. Amin K, Dannenfelser RM. In vitro hemolysis: guidance for the pharmaceutical scientist. J Pharm Sci. 2006;95(6):1173-1176.
14. ASTM. Protocol F756: Standard practice for the assessment of hemolytic properties of materials. Available from: http://www.astm.org/ Standards/F756.htm. Accessed December 6, 2011.
15. Dal Negro G, Cristofori P. A new approach for evaluation of the in vitro hemolytic potential of a solution of a new medicine. Comp Haematol Int. 1996;6(1):35-41.
16. Oudiz RJ, Widlitz A, Beckmann XJ, et al. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest. 2004;126(1):90-94.
17. Skrinska V, Lucas FV. Isolation of prostacyclin from whole blood. Prostaglandins. 1981;22(3):365-375.
18. Cho MJ. Reduced hydrolytic lability of epoprostenol in the presence of cationic micelles. J Pharm Sci. 1982;71(4):453-454.
19. Shukla D, Trout BL. Interaction of arginine with proteins and the mechanism by which it inhibits aggregation. J Phys Chem B. 2010;114(42):13426-13438.
20. Nicolas LB, Gutierrez MM, Galitz L, Dingemanse J. Epoprostenol with expanded stability has the same pharmacokinetic and pharmacodynamic profiles as epoprostenol in healthy subjects. Eur Resp J. 2011;38(Suppl 55): 408S.